• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, September 26, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

UC researcher urges caution using remdesivir to treat COVID-19

Bioengineer by Bioengineer
December 30, 2020
in Chemistry
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Pharmaceutical scientist sees potential problems with remdesivir as a COVID-19 treatment

IMAGE

Credit: University of Cincinnati

While the world has its eyes on vaccines to stop the spread of coronavirus, therapeutics are still necessary to treat hospitalized patients. One of these treatments, remdesivir, is the first and only antiviral agent of its kind that the U.S. Food and Drug Administration (FDA) has approved so far for COVID-19.

Research at the University of Cincinnati, however, contends that this antiviral drug is being used too indiscriminately when treating patients hospitalized with the virus. The study is published in the journal Fundamental & Clinical Pharmacology.

The FDA approved remdesivir, marketed as Veklury, for emergency use authorization in May 2020 to treat COVID-19 and granted full approval for treatment in October 2020. The World Health Organization came out in November 2020 with a conditional recommendation advising against its use entirely citing: “More research is needed, especially to provide higher certainty of evidence for specific groups of patients.”

In the UC study, lead author Bingfang Yan, a pharmaceutical scientist, and his UC graduate students Yue Shen and William Eades, found that the drug permanently stops the activity of an enzyme called CES-2, which is found in the intestine, liver and kidney and is needed for the breakdown of many medications.

“This enzyme normally breaks down and activates medicines in certain antivirals or inactivates other medicines such in certain anticoagulants,” says Yan, professor at the James L. Winkle College of Pharmacy. On the other hand, he says this breakdown increases the toxicity of many more medications such as with heart medicines and anticancer drugs.

An antiviral is a drug against viruses and an anticoagulant is a drug that hinders the clotting of blood.
What further complicates the issue, Yan says, is that when delivered through an IV, remdesivir does not treat the virus unless the body has additional specific enzymes, which are not found in all patients. It can also cause other antiviral drugs, such as those used for HIV/AIDs and hepatitis C, to not work properly.

Remdesivir is only administered through the veins in a hospital setting, with the FDA typically recommending a dose of once a day, for approximately 10 days, and “intravenous injection of remdesivir can cause safety concerns because of high initial concentrations of the drug in the system,” says Yan, noting, “If physicians use it, they have to use it with caution.”

He adds, “Clearly, the treatment should be used for the right patients and in the proper dosages with care when used in combination with other medications.”

###

Yan’s UC laboratory studies how drugs are metabolized in the body to see if certain people should or should not use the drug or use it at a different dose. He has, for decades, been supported by the National Institutes of Health.

Media Contact
Angela Koenig
[email protected]

Related Journal Article

http://dx.doi.org/10.1111/fcp.12643

Tags: Clinical TrialsCritical Care/Emergency MedicineInfectious/Emerging DiseasesMedicine/HealthMetabolism/Metabolic DiseasesPharmaceutical SciencePharmaceutical SciencesPublic HealthToxicologyVirology
Share13Tweet8Share2ShareShareShare2

Related Posts

Fluorogenic Probes Unveil Ferroptosis Onset, Progression

September 26, 2025
Cutting-Edge Adaptive Optics Boost Gravitational-Wave Discoveries

Cutting-Edge Adaptive Optics Boost Gravitational-Wave Discoveries

September 26, 2025

Jingyuan Xu of KIT Honored with “For Women in Science” Sponsorship Award

September 26, 2025

Deep Learning Revolutionizes Multiscale Design of Porous Electrodes in Flow Cells

September 26, 2025
Please login to join discussion

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    81 shares
    Share 32 Tweet 20
  • Physicists Develop Visible Time Crystal for the First Time

    72 shares
    Share 29 Tweet 18
  • Scientists Discover and Synthesize Active Compound in Magic Mushrooms Again

    55 shares
    Share 22 Tweet 14
  • Tailored Gene-Editing Technology Emerges as a Promising Treatment for Fatal Pediatric Diseases

    51 shares
    Share 20 Tweet 13

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Fluorogenic Probes Unveil Ferroptosis Onset, Progression

UCLA Unveils Innovative Light-Based System for Sustainable Generative AI

Cancer patients undergoing treatment late in life face increased hospital, emergency, and ICU admissions, with reduced hospice care utilization

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.